Richard DiMarchi, MBX Biosciences

Suc­cess­ful sci­en­tist-in­vestor al­lies team up again — this time for a stab at rare meta­bol­ic dis­ease

A sci­en­tist-ex­ec­u­tive team that, over the last decade, sold one di­a­betes biotech to Roche for up-to $537 mil­lion and two oth­ers to No­vo Nordisk for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.